Compare PED & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | EQ |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 57.8M |
| IPO Year | N/A | 2018 |
| Metric | PED | EQ |
|---|---|---|
| Price | $0.54 | $1.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $1.50 | $1.00 |
| AVG Volume (30 Days) | 169.0K | ★ 510.3K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $33,244,999.00 | $4,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | N/A |
| P/E Ratio | $5.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.43 | $0.27 |
| 52 Week High | $1.00 | $2.35 |
| Indicator | PED | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 56.95 |
| Support Level | $0.55 | $0.84 |
| Resistance Level | $0.61 | $1.44 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 49.92 | 60.99 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.